TY - JOUR
T1 - Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients
T2 - A cross-sectional study
AU - Kuo, Te Hui
AU - Lin, Wei Hung
AU - Chao, Jo Yen
AU - Wu, An Bang
AU - Tseng, Chin Chung
AU - Chang, Yu Tzu
AU - Liou, Hung Hsiang
AU - Wang, Ming Cheng
N1 - Funding Information:
This research was supported by the grants from National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan (grant numbers: NCKUH-10406030, NCKUH-10505030, and NCKUH-10704006). The funder had no role in study design, conduct of the study, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/7/17
Y1 - 2019/7/17
N2 - Background: Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD)-mineral and bone disorder (MBD), which has various forms of presentation, from osteoporosis to vascular calcification. The positive association of sclerostin with bone mineral density (BMD) has been demonstrated in CKD and hemodialysis (HD) patients but not in peritoneal dialysis (PD) patients. This study assessed the association between sclerostin and BMD in PD patients. Methods: Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD-MBD-related markers. BMD was also assessed simultaneously. We examined the relationship between sclerostin and each parameter through Spearman correlation analysis and by comparing group data between patients with above- and below-median sclerostin levels. Univariate and multiple logistic regression models were employed to define the most predictive of sclerostin levels in the above-median category. Results: Bivariate analysis revealed that sclerostin was correlated with spine BMD (r = 0.271, P = 0.011), spine BMD T-score (r = 0.274, P = 0.010), spine BMD Z-score (r = 0.237, P = 0.027), and intact parathyroid hormone (PTH; r = - 0.357, P < 0.001) after adjustments for age and sex. High BMD, old age, male sex, increased weight and height, diabetes, and high osteocalcin and uric acid levels were observed in patients with high serum sclerostin levels and an inverse relation was noticed between PTH and sclerostin. Univariate logistic regression analysis demonstrated that BMD is positively correlated with above-median sclerostin levels (odds ratio [OR] = 65.61, P = 0.002); the correlation was retained even after multivariate adjustment (OR = 121.5, P = 0.007). Conclusions: For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.
AB - Background: Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD)-mineral and bone disorder (MBD), which has various forms of presentation, from osteoporosis to vascular calcification. The positive association of sclerostin with bone mineral density (BMD) has been demonstrated in CKD and hemodialysis (HD) patients but not in peritoneal dialysis (PD) patients. This study assessed the association between sclerostin and BMD in PD patients. Methods: Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD-MBD-related markers. BMD was also assessed simultaneously. We examined the relationship between sclerostin and each parameter through Spearman correlation analysis and by comparing group data between patients with above- and below-median sclerostin levels. Univariate and multiple logistic regression models were employed to define the most predictive of sclerostin levels in the above-median category. Results: Bivariate analysis revealed that sclerostin was correlated with spine BMD (r = 0.271, P = 0.011), spine BMD T-score (r = 0.274, P = 0.010), spine BMD Z-score (r = 0.237, P = 0.027), and intact parathyroid hormone (PTH; r = - 0.357, P < 0.001) after adjustments for age and sex. High BMD, old age, male sex, increased weight and height, diabetes, and high osteocalcin and uric acid levels were observed in patients with high serum sclerostin levels and an inverse relation was noticed between PTH and sclerostin. Univariate logistic regression analysis demonstrated that BMD is positively correlated with above-median sclerostin levels (odds ratio [OR] = 65.61, P = 0.002); the correlation was retained even after multivariate adjustment (OR = 121.5, P = 0.007). Conclusions: For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.
UR - http://www.scopus.com/inward/record.url?scp=85069499430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069499430&partnerID=8YFLogxK
U2 - 10.1186/s12882-019-1452-5
DO - 10.1186/s12882-019-1452-5
M3 - Article
C2 - 31315601
AN - SCOPUS:85069499430
SN - 1471-2369
VL - 20
JO - BMC Nephrology
JF - BMC Nephrology
IS - 1
M1 - 266
ER -